Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director · President and CEO | February 20, 2026 | February 20, 2026 |
| Seer, Inc.SEER · Entity 6717 | Director | June 12, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 447,150 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 151,700 · Balance 447,150 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 682,500 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Grant · Acquired 682,500 · Balance 682,500 F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 3,369,395 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,369,395 F2: Shares are held by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Shares are held by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse.
F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Seer, Inc.
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 87,615 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 58,178 · Balance 87,615 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 20, 2026 17:26 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 682,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001670579-26-000002 · wk-form4_1771626383.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 682,500 Underlying: Common Stock · 682,500 shares Expires 2036-02-19 F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 17:26 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 151,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001670579-26-000002 · wk-form4_1771626383.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,150 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 08:01 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | PurchaseCommon Stock | 20,000 | $1.02 | $20,400.00 |
DisclosureSEC source: 0001670579-25-000008 · wk-form4_1742212876.xml · nonDerivative · entry 2 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 3,369,395 F1 · price: This transaction was executed in multiple trades on 3/14/2025 at prices ranging from $1.00 to $1.03 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the specified range. F2 · ownership.nature: Shares are held by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:21 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 618,250 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001670579-25-000003 · wk-form4_1740187261.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,250 Underlying: Common Stock · 618,250 shares Expires 2035-02-19 F3 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:21 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 136,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001670579-25-000003 · wk-form4_1740187261.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,450 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:22 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 58,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016907 · form4-06142024_080648.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,615 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:18 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 546,950 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006421 · wk-form4_1708640281.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546,950 Underlying: Common Stock · 546,950 shares Expires 2034-02-19 F3 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:18 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 118,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006421 · wk-form4_1708640281.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,700 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2025, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:17 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 34,735 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001209191-23-038191 · doc4.xml · derivative · entry 2 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,735 Underlying: Class A Common Stock · 34,735 shares Expires 2033-06-14 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:17 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 23,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038191 · doc4.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,437 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 16:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001619856-23-000073 · wk-form4_1686342698.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,350 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to the option vested on the corresponding day of each month thereafter until the option became fully vested on June 12, 2022. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 16:31 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 10,000 | $2.96 | $29,600.00 |
DisclosureSEC source: 0001619856-23-000073 · wk-form4_1686342698.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 16:16 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001619856-23-000039 · wf-form4_167951616420908.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,350 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to the option vested on the corresponding day of each month thereafter until the option became fully vested on June 12, 2022. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 16:16 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 10,000 | $2.96 | $29,600.00 |
DisclosureSEC source: 0001619856-23-000039 · wf-form4_167951616420908.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 17:14 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 510,500 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000028 · wf-form4_167719043346430.xml · derivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,500 Underlying: Common Stock · 510,500 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:40 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 17,865 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001209191-22-038103 · doc4.xml · derivative · entry 2 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,865 Underlying: Class A Common Stock · 17,865 shares Expires 2031-06-15 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:40 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 5,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038103 · doc4.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,994 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 09, 2022 Filed May 10, 2022 19:32 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-22-028170 · doc4.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,350 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021. F3 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to this option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 09, 2022 Filed May 10, 2022 19:32 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 10,000 | $2.96 | $29,600.00 |
DisclosureSEC source: 0001209191-22-028170 · doc4.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021. Read SEC document |
| January 26, 2022 Filed Jan 27, 2022 16:41 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-22-005222 · doc4.xml · derivative · entry 2 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,350 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021. F2 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on June 12, 2022, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document |
| January 26, 2022 Filed Jan 27, 2022 16:41 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 10,000 | $2.96 | $29,600.00 |
DisclosureSEC source: 0001209191-22-005222 · doc4.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,359,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2022 Filed May 10, 2022 19:29 UTC Amendment | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionOption to purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-22-028169 · doc4a.xml · derivative · entry 3 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,350 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021. F4 · derivative.exercise_date: 1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to this option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| January 26, 2022 Filed May 10, 2022 19:29 UTC Amendment | Caribou Biosciences, Inc. CRBU · Entity 6445 | Exercise / conversionCommon Stock | 10,000 | $2.96 | $29,600.00 |
DisclosureSEC source: 0001209191-22-028169 · doc4a.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021. F2 · balance_after: This Form 4/A is being filed to correct an inadvertent error in the original Form 4 filed January 27, 2022 attributing direct ownership of 3,349,395 shares listed in column 5 to the reporting person. As described in a Form 5 filed on February 9, 2022, on September 27, 2021, these 3,349,395 shares were transferred to a trust for which the reporting person and her spouse serve as a Co-Trustees. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 17:27 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 411,000 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070804 · doc4.xml · derivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,000 Underlying: Common Stock · 411,000 shares Expires 2031-12-19 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on December 20, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 09, 2021 Filed Nov 13, 2021 00:45 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $35.25 | $0.00 |
DisclosureSEC source: 0001209191-21-064362 · doc4.xml · derivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Stock · 30,000 shares Expires 2031-11-09 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on December 9, 2021. Read SEC document |
| September 27, 2021 Filed Feb 9, 2022 16:25 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GiftCommon Stock | 3,349,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008027 · doc5.xml · nonDerivative · entry 2 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,349,395 F1 · shares: Represents transfer of shares to The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse. F2 · ownership.nature: Shares are held by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse. Read SEC document |
| September 27, 2021 Filed Feb 9, 2022 16:25 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GiftCommon Stock | 3,349,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008027 · doc5.xml · nonDerivative · entry 1 Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents transfer of shares to The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.